Mesoblast Limited (ASX:MSB) Chief Executive, Professor Silviu Itescu, today provided shareholders at Mesoblast's Annual General Meeting with an overview of the company's corporate strategy and major highlights of recent achievements.
Mesoblast Limited (ASX:MSB) Chairman's Address and CEO's Presentation to Shareholders
Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the key elements of the company's first clinical trial using intravenous delivery of its proprietary allogeneic, or off-the-shelf, mesenchymal precursor cell (MPC) technology in patients with Type 2 Diabetes. Based on the positive outcome of the FDA meeting held on November 18, Mesoblast will file an Investigational New Drug (IND) submission within the next 30-60 days to seek clearance for patient recruitment.
Regenerative medicine company Mesoblast Limited (ASX:MSB) today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor(TM) after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months. The Phase 2 trial results in 60 patients were presented at the American Heart Association annual meeting in Orlando, Florida, by the trial's independent principal investigator Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute in Houston.
Regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that a single intravenous injection of its proprietary adult stem cells resulted in significant lowering of blood sugar levels for up to eight weeks in a controlled, randomized preclinical trial in non-human primates with Type 2 diabetes. This was accompanied by significant reductions in circulating inflammatory markers to levels associated with protection against heart attacks and death in patients with Type 2 diabetes. Results of the study were presented at the Credit Suisse Healthcare conference in Phoenix, Arizona.
Asian Activities Report for November 1, 2011 includes: Montezuma Mining Company Ltd (ASX:MZM) reports outstanding copper results from a recently completed 19-hole drilling programme at the Company's 100% owned Butcherbird Copper Project in Western Australia; Hannans Reward Ltd (ASX:HNR) provides an update on its drilling program currently underway at the Jigalong Project; Biomedical company, Tissue Therapies Limited (ASX:TIS) says today that the VitroGro(R) synthetic protein has been classified as a biologic product by the US Food and Drug Administration; Navigator Resources Limited (ASX:NAV) has achieved the production milestone of 100,000 ounces of gold poured since it commenced operation at the Company's Bronzewing Gold Project, located 960km northeast of Perth.
Agenix Limited (ASX:AGX) is pleased to provide Chairman's Address to shareholders at 2011 Annual General Meeting.
